Summit Partners Public Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Summit Partners Public Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-47,910	Closed	-$15.2M	–	196
2023 Q4	$15.2M	Sell	47,910 -49,467	-51%	-$9.62M	0.63%	64
2023 Q3	$16.5M	Buy	97,377 +16,896	+21%	+$3.18M	0.72%	55
2023 Q2	$17.5M	Buy	80,481 +28,381	+54%	+$6.08M	0.65%	54
2023 Q1	$9.46M	Buy	+52,100	New	+$9.96M	0.39%	76

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Summit Partners Public Asset Management's KRTX Position: Q1 2024 in Review

Summit Partners Public Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 47,910 shares — an estimated $15.2M sold.

Summit Partners Public Asset Management first reported a position in KRTX in Q1 2023 and held it in 4 quarters. The position peaked at $17.5M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Summit Partners Public Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Summit Partners Public Asset Management sold 47,910 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $15.2M.
Summit Partners Public Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
Summit Partners Public Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $17.5M in Q2 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2024, filed 15 May 2024.